Selvita S.A. | Cash Flow

Fiscal year is January-December. All values PLN Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
2,385.40
5,850.10
6,233.00
2,685.40
6,731.90
892.50
Depreciation, Depletion & Amortization
2,082.50
2,354.40
3,432.80
3,617.50
5,240.10
8,225.10
Other Funds
9,641.90
8,548.50
18,297.00
19,934.60
18,914.40
12,824.30
Funds from Operations
242.60
8,250.90
14,719.50
7,670.30
13,771.30
3,706.80
Changes in Working Capital
6,744.30
13,173.80
30,682.00
13,671.90
2,955.80
31,779.80
Net Operating Cash Flow
6,986.90
4,922.90
15,962.50
6,001.50
10,815.50
35,486.60
Capital Expenditures
1,775.30
3,524.10
4,951.50
21,210.40
11,388.80
Sale of Fixed Assets & Businesses
-
-
-
-
10.00
Net Investing Cash Flow
2,471.80
3,610.40
5,125.90
18,673.50
21,580.90
Issuance/Reduction of Debt, Net
12.80
555.60
474.30
4,700.80
2,055.40
Net Financing Cash Flow
9,629.10
7,992.90
45,137.10
24,963.20
17,794.90
Net Change in Cash
170.40
540.50
24,048.70
288.10
7,029.50
Free Cash Flow
8,762.20
8,447.00
20,914.00
27,211.90
573.40
Other Sources
-
-
463.70
2,596.90
47.30
Change in Capital Stock
-
-
27,314.50
327.90
935.90
Other Uses
696.50
86.30
638.20
60.00
10,249.40

About Selvita

View Profile
Address
Park Life Science
Kraków MA 30
Poland
Employees -
Website http://www.selvita.com
Updated 07/08/2019
Selvita SA engages in the provision of products and solutions for the pharmaceutical and biotechnology industry. It operates through the following segments: Innovation, Services, and Bioinformatics. The Innovation segment focuses on the small-molecule marketing activities of the pharmacological action, which is the next stage of the process of developing the commercialization process.